Citations

Showing 10 of 108094 citations.

Faculty Opinions recommendation of Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: A randomized clinical trial.
Lal, Devyani

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.726113355.793543770 Get It

Faculty Opinions recommendation of Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease.
Lal, Devyani

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725421418.793543775 Get It

Faculty Opinions recommendation of Efficacy of Reslizumab with Asthma, Chronic Sinusitis with Nasal Polyps and Elevated Blood Eosinophils.
Lal, Devyani

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732835922.793543763 Get It

Faculty Opinions recommendation of Serum periostin, IgE, and SE-IgE can be used as biomarkers to identify moderate to severe chronic rhinosinusitis with nasal polyps.
Lal, Devyani

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.731981236.793543767 Get It

Faculty Opinions recommendation of Immunopathogenesis of chronic rhinosinusitis and nasal polyposis.
Lal, Devyani

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727104855.793543765 Get It

Faculty Opinions recommendation of Perinatal Activation of the Interleukin-33 Pathway Promotes Type 2 Immunity in the Developing Lung.
Lal, Devyani

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727097371.793543761 Get It

Faculty Opinions recommendation of The role of interleukin-33 in chronic rhinosinusitis.
Lal, Devyani

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.727022415.793543762 Get It

Faculty Opinions recommendation of Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
Lal, Devyani

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.725511220.793543766 Get It

Management of Sacrococcygeal Chordoma
Ahmed, Ahmed T. , Morsy, Mohamed , Mustafa, Karim, Testini, Paola, Aleem, Ilyas , Murad, M. Hassan , Murad, Mohammad Hassan, Murad, M Hassan , Abdel-Rahman, Omar Mohammed , Nassr, Ahmad

Mayo Clinic

Spine | March 14, 2018 | Volume: 43 | Issue: 19 | Pages: E1157-E1169

10.1097/brs.0000000000002638 | PMID 29538244 Get It

Study Design. Systematic review and meta-analysis of observational studies. Objective. The aim of the study is to evaluate different treatment modalities in the management of sacrococcygeal chordoma. Summary of Background Data. Chordomas are primary malignant bone tumors associated with considerable morbidity and mortality. Methods. We searched MEDLINE, EMBASE, Cochrane Central-Register of Controlled Trials, and Scopus from inception to July 2015. Eligible studies included patients with sacrococcygeal chordoma treated exclusively with surgery, radiotherapy, or both. Two reviewers independently assessed the eligibility of potential studies, risk of bias, and extracted data. Outcomes of interest were all-cause mortality, progression-free survival, and metastases. We analyzed further surgical outcomes by resection margin. All outcomes were assessed at 60 months and more than 60 months following intervention. Results. We included 33 noncomparative studies reporting on 501 patients (mean age 57 years). Overall mortality rate was (16%) after surgical resection with adjuvant radiotherapy and (28%) after surgical resection, and (43%) after radiotherapy (P = 0.28). All-cause mortality following wide surgical resection was (32%) compared to (40%) after marginal resection (P = 0.51). Overall progression-free survival rate was (58%) after surgical resection with adjuvant radiotherapy and (55%) after surgery (P = 0.92). However, at more than 60 months follow-up, progression-free survival rates were significantly higher (P = 0.024) following surgical resection with adjuvant radiotherapy (74%) in comparison to surgery (55%) and radiotherapy (36%). Overall progression-free survival rates were nonsignificantly higher after wide surgical resection (66%) than marginal resection (33%) (P = 0.16). However, at 60 months follow-up, progression-free survival rates were significantly higher following wide surgical resection (73%) than marginal resection (33%) (P = 0.047). Conclusion. Sacrococcygeal chordoma is a difficult to treat disease entity. Until comparative studies become available, wide surgical resection and multidisciplinary management are the recommended approaches to improve patient outcomes. Level of Evidence: 3
Faculty Opinions recommendation of Tezepelumab in Adults with Uncontrolled Asthma.
Lal, Devyani

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | March 14, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.730845215.793543759 Get It